Bhavneesh Sharma

Investing In The Future Of Cataract Surgery: The RxSight Advantage (NASDAQ:RXST)

Blue Owl Capital Corporation is the leading publicly traded BDC specialized in senior secured loans for US middle market companies. Learn more on OBDC stock here.

Preferred stocks, REITs, MLPs, and exchange-traded debt offer attractive yields for income investors. Explore more details here.

Catalyst Pharmaceuticals has two FDA-approved products, Firdapse and Fycompa, with 92% annual revenue growth. Read more here.

Ambrx Biopharma Inc.’s selloff after Phase 1/2 ESMO data release presents a buying opportunity for its ADC candidates. Click here for my view of AMAN stock now.

Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. Read more here.

Vutrisiran, Alnylam Pharmaceuticals Inc.’s next-generation inverse RNA or RNAi candidate, has a high probability of success. Learn more about ALNY stock here.

Rhythm Pharmaceuticals, Inc. aims to treat orphan obesity disorders through Imcivree, with Q2 2023 revenue doubling. Click for my update on RYTM stock prospects.

ESSA has been in the investor spotlight after the recently presented data for its product candidate EPI-7386 with Xtandi. Read why EPIX stock is a Buy.

Prime Medicine’s technology originated at Harvard/MIT and has been termed as CRISPR 3.0. Check why I picked up a long position in Prime Medicine with a long-term timeframe.